文献速递基础与转化研究组学、生物样本库与精准医学

女性化性别肯定激素治疗期间血浆蛋白质组的适应性变化

Plasma proteome adaptations during feminizing gender-affirming hormone therapy.
PubMed 文献 · Nat Med · 2025-10-20

本研究对40名接受雌二醇联合醋酸环丙孕酮或螺内酯的女性化性别肯定激素治疗(GAHT)的跨性别者进行为期6个月的血浆蛋白质组分析,发现两种抗雄激素方案分别改变245和91种蛋白质(多数下降),蛋白质组向顺性别女性特征重塑,并与生殖能力、免疫调节和长期健康结局相关。

要点

  • 女性化GAHT使血浆蛋白质组向顺性别女性特征重塑,醋酸环丙孕酮和螺内酯分别改变245和91种蛋白质。
  • 醋酸环丙孕酮组睾酮水平显著下降,螺内酯组下降较少;男性精子发生相关蛋白质在醋酸环丙孕酮组显著下降。
  • GAHT使蛋白质谱偏向哮喘和自身免疫相关特征,醋酸环丙孕酮则使其偏离动脉粥样硬化相关特征。

核心结论

  • 女性化GAHT以激素依赖的方式重塑血浆蛋白质组,对生殖能力、免疫调节和长期健康结局具有意义。

研究设计与样本

  • 研究纳入40名接受女性化GAHT的跨性别者,治疗方案为雌二醇联合醋酸环丙孕酮或螺内酯,随访6个月,检测血浆蛋白质组变化。

主要发现

  • 在测量的5,279种蛋白质中,醋酸环丙孕酮组和螺内酯组分别有245种和91种蛋白质水平发生变化,其中大多数(>95%)表现为下降。
  • 醋酸环丙孕酮组睾酮水平显著下降,螺内酯组下降较少;男性精子发生相关蛋白质在醋酸环丙孕酮组显著下降,归因于睾酮的丢失。
  • GAHT后体脂百分比和乳房体积的变化也反映在血浆蛋白质组中,包括瘦素表达增加。
  • 女性化GAHT使蛋白质组向顺性别女性特征重塑,分别改变了UK Biobank成人数据中前100种性别相关蛋白质中的36种(醋酸环丙孕酮)和22种(螺内酯)。
  • 醋酸环丙孕酮影响的蛋白质中有43%与顺性别女性绝经期激素治疗改变的蛋白质重叠且方向相同, notable例外包括CXCL13和NOS3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sex differences manifest in various traits, as well as in the risk of cardiovascular, metabolic and immunological conditions. Despite the clear physical changes induced by gender-affirming hormone therapy (GAHT), little is known about how it affects underlying physiological and biochemical processes. Here we examined plasma proteome changes over 6 months of feminizing GAHT in 40 transgender individuals treated with estradiol plus one of two antiandrogens: cyproterone acetate or spironolactone. Testosterone levels dropped markedly in the cyproterone group, but less so in those receiving spironolactone. Among 5,279 total proteins measured, feminizing GAHT changed the levels of 245 and 91, in the cyproterone and spironolactone groups, respectively, with most (>95%) showing a decrease. Proteins associated with male spermatogenesis showed a marked decrease in the cyproterone group, attributable specifically to loss of testosterone. Changes in body fat percentage and breast volume following GAHT were also reflected in the plasma proteome, including an increase in leptin expression. We show that feminizing GAHT remodels the proteome toward a cis-female profile, altering 36 (cyproterone) and 22 (spironolactone) of the top 100 sex-associated proteins in UK Biobank adult data. Moreover, 43% of cyproterone-affected proteins overlapped with those altered by menopausal hormone therapy in cis women, showing the same directional changes, with notable exceptions including CXCL13 and NOS3. Feminizing GAHT skewed the protein profile toward that linked to asthma and autoimmunity, while GAHT with cyproterone specifically skewed it away from an atherosclerosis-associated profile, suggesting a protective effect. These results reveal that feminizing GAHT reshapes the plasma proteome in a hormone-dependent manner, with implications for reproductive capacity, immune regulation and long-term health outcomes.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Nguyen NNL, Celestra D, Angus LM, et al. Plasma proteome adaptations during feminizing gender-affirming hormone therapy. Nat Med. 2025. PMID: 41115957. doi:10.1038/s41591-025-04023-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。